• Consensus Rating: Hold
  • Consensus Price Target: $242.68
  • Forecasted Upside: 65.69%
  • Number of Analysts: 29
  • Breakdown:
  • 0 Sell Ratings
  • 16 Hold Ratings
  • 13 Buy Ratings
  • 0 Strong Buy Ratings
$146.47
▼ -0.92 (-0.62%)

This chart shows the closing price for BIIB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
OctNovDec$146.47Closing price on 12/20/24:
Get New Biogen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BIIB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIIB

Analyst Price Target is $242.68
▲ +65.69% Upside Potential
This price target is based on 29 analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $242.68, with a high forecast of $342.00 and a low forecast of $164.00. The average price target represents a 65.69% upside from the last price of $146.47.

This chart shows the closing price for BIIB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
12/233/246/249/2412/241/26$103$162$222$282$342Closing price on 12/20/24: $146.47High$342.00Average$242.68Low$164.00




Current Consensus is Hold

The current consensus among 29 investment analysts is to hold stock in Biogen. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 21 buy ratings
  • 5 hold ratings
  • 0 sell ratings
6/29/2023
  • 0 strong buy ratings
  • 22 buy ratings
  • 5 hold ratings
  • 0 sell ratings
9/27/2023
  • 0 strong buy ratings
  • 20 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/26/2023
  • 0 strong buy ratings
  • 19 buy ratings
  • 8 hold ratings
  • 0 sell ratings
3/25/2024
  • 0 strong buy ratings
  • 17 buy ratings
  • 9 hold ratings
  • 0 sell ratings
6/23/2024
  • 0 strong buy ratings
  • 17 buy ratings
  • 8 hold ratings
  • 0 sell ratings
9/21/2024
  • 0 strong buy ratings
  • 15 buy ratings
  • 13 hold ratings
  • 0 sell ratings
11/20/2024
  • 0 strong buy ratings
  • 14 buy ratings
  • 15 hold ratings
  • 0 sell ratings
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 13 buy ratings
  • 16 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/20/2024BMO Capital MarketsDowngradeOutperform ➝ Market Perform$230.00 ➝ $164.00
12/16/2024Stifel NicolausDowngradeBuy ➝ Hold$175.00
12/10/2024Bank of AmericaReiterated RatingNeutral$178.00
12/9/2024Jefferies Financial GroupDowngradeBuy ➝ Hold$250.00 ➝ $180.00
11/21/2024MizuhoLower TargetOutperform ➝ Outperform$251.00 ➝ $207.00
11/18/2024Needham & Company LLCDowngradeBuy ➝ Hold$270.00 ➝ $270.00
11/15/2024Wolfe ResearchInitiated CoveragePeer Perform
11/15/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$294.00 ➝ $300.00
11/14/2024CitigroupInitiated CoverageNeutral$190.00
11/13/2024CitigroupUpgradeHold
11/4/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$220.00 ➝ $210.00
10/31/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$190.00 ➝ $180.00
10/31/2024OppenheimerLower TargetOutperform ➝ Outperform$270.00 ➝ $255.00
10/31/2024TD CowenLower TargetBuy ➝ Buy$300.00 ➝ $275.00
10/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$300.00 ➝ $300.00
10/31/2024Morgan StanleyDowngradeOverweight ➝ Equal Weight$285.00 ➝ $204.00
10/30/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$270.00 ➝ $270.00
10/17/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$260.00 ➝ $230.00
10/10/2024Raymond JamesReiterated RatingMarket Perform
10/4/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$292.00 ➝ $269.00
10/3/2024UBS GroupLower TargetNeutral ➝ Neutral$234.00 ➝ $202.00
9/24/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$285.00 ➝ $285.00
9/23/2024WedbushLower TargetNeutral ➝ Neutral$210.00 ➝ $205.00
9/19/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$292.00 ➝ $292.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$292.00 ➝ $292.00
9/4/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$285.00 ➝ $285.00
8/19/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$285.00 ➝ $285.00
8/6/2024MizuhoLower TargetOutperform ➝ Outperform$277.00 ➝ $251.00
8/5/2024Truist FinancialReiterated RatingBuy ➝ Buy$340.00 ➝ $302.00
8/2/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$282.00 ➝ $292.00
8/2/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$240.00 ➝ $225.00
8/2/2024ScotiabankLower TargetSector Outperform ➝ Sector Outperform$275.00 ➝ $244.00
8/2/2024WedbushLower TargetNeutral ➝ Neutral$215.00 ➝ $210.00
8/2/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$200.00 ➝ $190.00
8/1/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$288.00 ➝ $288.00
7/29/2024Robert W. BairdLower TargetOutperform ➝ Outperform$316.00 ➝ $294.00
7/26/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$294.00 ➝ $294.00
7/12/2024Piper SandlerLower TargetOverweight ➝ Overweight$335.00 ➝ $313.00
7/3/2024William BlairReiterated RatingOutperform
6/28/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$294.00 ➝ $294.00
6/26/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$317.00 ➝ $317.00
6/5/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$317.00 ➝ $317.00
5/29/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$317.00
5/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$300.00 ➝ $300.00
5/22/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$294.00
5/16/2024Truist FinancialReiterated RatingBuy ➝ Buy$340.00 ➝ $340.00
5/3/2024HSBCBoost TargetBuy ➝ Buy$339.00 ➝ $342.00
4/29/2024OppenheimerReiterated RatingOutperform ➝ Outperform$270.00 ➝ $270.00
4/25/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$215.00 ➝ $200.00
4/25/2024WedbushBoost TargetNeutral ➝ Neutral$213.00 ➝ $215.00
4/25/2024HC WainwrightLower TargetBuy ➝ Buy$325.00 ➝ $300.00
4/24/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$294.00
4/19/2024OppenheimerLower TargetOutperform ➝ Outperform$290.00 ➝ $270.00
4/17/2024UBS GroupLower TargetNeutral ➝ Neutral$250.00 ➝ $214.00
4/17/2024WedbushLower TargetNeutral ➝ Neutral$245.00 ➝ $213.00
4/12/2024Bank of AmericaLower TargetNeutral ➝ Neutral$280.00 ➝ $260.00
4/11/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$270.00 ➝ $240.00
4/4/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$230.00 ➝ $215.00
4/1/2024William BlairReiterated RatingOutperform
3/25/2024Truist FinancialReiterated RatingBuy ➝ Buy$340.00
3/5/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$364.00
2/22/2024MizuhoLower TargetBuy ➝ Buy$355.00 ➝ $277.00
2/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$311.00
2/20/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$310.00 ➝ $305.00
2/16/2024UBS GroupLower TargetNeutral ➝ Neutral$276.00 ➝ $250.00
2/14/2024Robert W. BairdLower TargetOutperform ➝ Outperform$333.00 ➝ $316.00
2/14/2024Piper SandlerLower TargetOverweight ➝ Overweight$350.00 ➝ $325.00
2/14/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$295.00 ➝ $285.00
2/14/2024OppenheimerLower TargetOutperform ➝ Outperform$295.00 ➝ $290.00
2/14/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$379.00 ➝ $364.00
2/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$325.00
2/14/2024Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$315.00 ➝ $240.00
2/13/2024Needham & Company LLCLower TargetBuy ➝ Buy$305.00 ➝ $300.00
2/12/2024Royal Bank of CanadaBoost TargetOverweight ➝ Overweight$363.00 ➝ $379.00
2/12/2024Bank Of America (Bofa)Lower TargetNeutral ➝ Neutral$290.00 ➝ $280.00
2/12/2024WedbushBoost TargetNeutral ➝ Neutral$239.00 ➝ $245.00
1/30/2024OppenheimerReiterated RatingOutperform ➝ Outperform$295.00
1/24/2024UBS GroupDowngradeBuy ➝ Neutral$311.00 ➝ $276.00
1/10/2024William BlairReiterated RatingOutperform
1/7/2024BTIG ResearchReiterated RatingNeutral
12/20/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$311.00
12/18/2023OppenheimerBoost TargetOutperform ➝ Outperform$280.00 ➝ $295.00
12/14/2023Stifel NicolausLower TargetBuy ➝ Buy$315.00 ➝ $287.00
12/7/2023Raymond JamesUpgradeMarket Perform ➝ Outperform$283.00
11/10/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$361.00 ➝ $373.00
11/9/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$351.00 ➝ $363.00
11/9/2023BMO Capital MarketsLower TargetOutperform ➝ Outperform$314.00 ➝ $295.00
11/9/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$343.00 ➝ $365.00
11/9/2023WedbushLower TargetNeutral ➝ Neutral$266.00 ➝ $239.00
11/9/2023William BlairReiterated RatingOutperform
11/8/2023UBS GroupLower TargetBuy ➝ Buy$327.00 ➝ $312.00
10/26/2023William BlairReiterated RatingOutperform
10/26/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$305.00
10/26/2023WedbushLower TargetNeutral ➝ Neutral$270.00 ➝ $266.00
10/11/2023Morgan StanleyLower TargetOverweight ➝ Overweight$381.00 ➝ $361.00
9/6/2023HSBCInitiated CoverageBuy$360.00
9/5/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$363.00 ➝ $381.00
8/29/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$354.00 ➝ $357.00
8/14/2023MizuhoLower TargetBuy ➝ Buy$340.00 ➝ $335.00
8/8/2023Truist FinancialLower TargetBuy ➝ Buy$340.00
8/8/2023BMO Capital MarketsLower TargetOutperform ➝ Outperform$347.00 ➝ $336.00
8/8/2023Atlantic SecuritiesLower TargetNeutral ➝ Neutral$282.00 ➝ $275.00
8/8/2023Needham & Company LLCLower TargetBuy ➝ Buy$323.00 ➝ $305.00
8/8/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$311.00 ➝ $294.00
8/7/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$374.00 ➝ $354.00
8/7/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$350.00 ➝ $343.00
8/7/2023Piper SandlerLower Target$380.00 ➝ $350.00
8/7/2023OppenheimerLower TargetOutperform ➝ Outperform$360.00 ➝ $290.00
8/7/2023Bank of AmericaLower Target$310.00 ➝ $290.00
8/7/2023WedbushLower Target$276.00 ➝ $269.00
8/7/2023Robert W. BairdLower Target$340.00 ➝ $333.00
7/31/2023Royal Bank of CanadaLower TargetOutperform$379.00 ➝ $374.00
7/27/2023ScotiabankInitiated CoverageSector Outperform$327.00
7/26/2023Royal Bank of CanadaBoost Target$341.00 ➝ $379.00
7/26/2023Needham & Company LLCBoost TargetBuy ➝ Buy$320.00 ➝ $323.00
7/26/2023Bank of AmericaLower Target$320.00 ➝ $310.00
7/26/2023BMO Capital MarketsLower TargetOutperform$357.00 ➝ $347.00
7/26/2023HC WainwrightReiterated RatingBuy ➝ Buy$325.00
7/25/2023Stifel NicolausLower TargetBuy$324.00 ➝ $320.00
7/25/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$320.00
7/24/2023UBS GroupLower TargetBuy$346.00 ➝ $335.00
7/18/2023BMO Capital MarketsLower Target$380.00 ➝ $357.00
7/11/2023Royal Bank of CanadaBoost Target$332.00 ➝ $341.00
6/12/2023OppenheimerBoost Target$350.00 ➝ $360.00
6/1/2023Piper SandlerBoost Target$346.00 ➝ $360.00
5/11/2023ArgusBoost Target$320.00 ➝ $350.00
5/4/2023Bank of AmericaBoost Target$300.00 ➝ $320.00
5/3/2023MizuhoBoost Target$315.00 ➝ $340.00
5/1/2023GuggenheimUpgradeNeutral ➝ Buy$270.00 ➝ $350.00
4/26/2023Royal Bank of CanadaLower Target$344.00 ➝ $340.00
4/26/2023Needham & Company LLCLower Target$325.00 ➝ $321.00
4/26/2023UBS GroupLower Target$347.00 ➝ $346.00
4/26/2023OppenheimerBoost Target$310.00 ➝ $325.00
4/26/2023BarclaysLower Target$307.00 ➝ $302.00
4/25/2023Morgan StanleyBoost Target$349.00 ➝ $371.00
4/21/2023Bank of AmericaBoost TargetNeutral$295.00 ➝ $300.00
4/17/2023WedbushBoost TargetNeutral$249.00 ➝ $263.00
4/17/2023ArgusBoost TargetBuy$315.00 ➝ $320.00
4/17/2023Piper SandlerUpgradeNeutral ➝ Overweight$280.00 ➝ $346.00
4/12/2023Morgan StanleyLower TargetOverweight$351.00 ➝ $349.00
4/12/2023BarclaysLower Target$310.00 ➝ $307.00
4/11/2023Needham & Company LLCReiterated RatingBuy$325.00
3/23/2023HC WainwrightReiterated RatingBuy$325.00
3/13/2023Royal Bank of CanadaBoost Target$335.00 ➝ $350.00
2/16/2023UBS GroupBoost TargetBuy$337.00 ➝ $340.00
2/16/2023HC WainwrightReiterated RatingBuy$325.00
2/16/2023Royal Bank of CanadaLower TargetOutperform$359.00 ➝ $333.00
2/16/2023CowenBoost TargetOutperform$300.00 ➝ $315.00
2/16/2023Morgan StanleyBoost TargetOverweight$345.00 ➝ $351.00
2/16/2023OppenheimerLower TargetOutperform$320.00 ➝ $310.00
2/15/2023Needham & Company LLCReiterated RatingBuy$325.00
1/25/2023Needham & Company LLCReiterated RatingBuy$325.00
1/24/2023Morgan StanleyBoost TargetOverweight$325.00 ➝ $345.00
12/1/2022The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$370.00
12/1/2022Atlantic SecuritiesBoost TargetNeutral$220.00 ➝ $295.00
11/30/2022MizuhoInitiated CoverageBuy$325.00
11/30/2022Jefferies Financial GroupBoost TargetBuy$325.00 ➝ $350.00
11/30/2022WedbushBoost TargetNeutral$218.00 ➝ $247.00
11/30/2022BarclaysBoost TargetEqual Weight$275.00 ➝ $313.00
11/15/2022Truist FinancialBoost TargetBuy$265.00 ➝ $350.00
11/14/2022OppenheimerBoost TargetOutperform$300.00 ➝ $315.00
11/11/2022GuggenheimBoost TargetNeutral$265.00 ➝ $270.00
11/1/2022MizuhoBoost TargetBuy$270.00 ➝ $325.00
10/28/2022OppenheimerReiterated RatingOutperform ➝ Outperform$300.00
10/26/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$285.00 ➝ $325.00
10/26/2022CowenBoost Target$270.00 ➝ $300.00
10/26/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$220.00 ➝ $370.00
10/26/2022Morgan StanleyBoost TargetOverweight$321.00 ➝ $325.00
10/26/2022CowenBoost Target$270.00 ➝ $300.00
10/26/2022Royal Bank of CanadaBoost TargetOutperform$310.00 ➝ $331.00
10/26/2022HC WainwrightBoost TargetBuy$240.00 ➝ $325.00
10/26/2022Atlantic SecuritiesBoost TargetNeutral$200.00 ➝ $220.00
10/26/2022Leerink PartnersBoost TargetOutperform$270.00 ➝ $310.00
10/24/2022Jefferies Financial GroupBoost TargetBuy$300.00 ➝ $325.00
10/13/2022Morgan StanleyBoost TargetOverweight$285.00 ➝ $321.00
10/12/2022Stifel NicolausUpgradeHold ➝ Buy$223.00 ➝ $299.00
10/7/2022ArgusUpgradeHold ➝ Buy$300.00
10/7/2022BarclaysBoost TargetEqual Weight$200.00 ➝ $275.00
10/6/2022UBS GroupBoost TargetBuy$238.00 ➝ $309.00
9/30/2022JPMorgan Chase & Co.Boost TargetNeutral$221.00 ➝ $275.00
9/29/2022OppenheimerBoost Target$230.00 ➝ $300.00
9/28/2022Piper SandlerBoost TargetNeutral$200.00 ➝ $280.00
9/28/2022Royal Bank of CanadaBoost Target$251.00 ➝ $321.00
9/28/2022Wells Fargo & CompanyBoost TargetOverweight$265.00 ➝ $350.00
9/28/2022WedbushBoost TargetNeutral$183.00 ➝ $217.00
9/28/2022Robert W. BairdUpgradeNeutral ➝ Outperform$224.00 ➝ $340.00
9/28/2022BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$217.00 ➝ $360.00
9/28/2022MizuhoUpgradeNeutral ➝ Buy$207.00 ➝ $270.00
9/22/2022Truist FinancialLower TargetBuy$270.00 ➝ $265.00
9/20/2022Jefferies Financial GroupReiterated RatingBuy ➝ Buy$300.00
9/12/2022Stifel NicolausLower TargetHold$230.00 ➝ $223.00
8/2/2022Robert W. BairdReiterated RatingNeutral ➝ Neutral$224.00
7/22/2022UBS GroupLower Target$238.00
7/22/2022GuggenheimLower Target$190.00
7/22/2022Robert W. BairdReiterated RatingNeutral ➝ Neutral$224.00
7/21/2022CowenLower TargetOutperform$285.00 ➝ $270.00
7/21/2022Truist FinancialLower TargetBuy$320.00 ➝ $270.00
7/21/2022Needham & Company LLCLower TargetBuy$262.00 ➝ $250.00
7/21/2022CowenLower Target$285.00 ➝ $270.00
7/21/2022BarclaysLower TargetEqual Weight$210.00 ➝ $200.00
7/20/2022Royal Bank of CanadaLower Target$264.00 ➝ $259.00
7/18/2022OppenheimerBoost TargetOutperform$225.00 ➝ $230.00
5/4/2022OppenheimerLower Target$240.00 ➝ $225.00
5/4/2022BarclaysLower Target$219.00 ➝ $210.00
4/28/2022WedbushReiterated RatingNeutral
4/21/2022Leerink PartnersLower TargetOutperform$300.00 ➝ $270.00
4/18/2022Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$235.00 ➝ $265.00
4/12/2022Morgan StanleyLower TargetOverweight$330.00 ➝ $283.00
4/12/2022BarclaysLower TargetEqual Weight$235.00 ➝ $219.00
4/8/2022Needham & Company LLCLower TargetBuy$290.00 ➝ $262.00
4/8/2022OppenheimerLower TargetOutperform$285.00 ➝ $240.00
3/28/2022Bank of AmericaLower TargetNeutral$230.00 ➝ $225.00
3/25/2022OppenheimerReiterated RatingOutperform ➝ Outperform$285.00
3/8/2022Stifel NicolausDowngradeBuy ➝ Hold$304.00 ➝ $223.00
3/3/2022Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$227.00 ➝ $248.00
2/7/2022Canaccord Genuity GroupLower TargetBuy$335.00 ➝ $305.00
2/4/2022CowenLower TargetOutperform$375.00 ➝ $285.00
2/4/2022Wolfe ResearchLower TargetPeer Perform$244.00 ➝ $217.00
2/4/2022Bank of AmericaLower TargetNeutral$245.00 ➝ $230.00
2/4/2022Needham & Company LLCLower TargetBuy$292.00 ➝ $290.00
2/4/2022Royal Bank of CanadaBoost TargetSector Perform$225.00 ➝ $227.00
2/4/2022WedbushLower TargetNeutral$195.00 ➝ $185.00
2/4/2022Wells Fargo & CompanyLower TargetEqual Weight$284.00 ➝ $235.00
2/4/2022Morgan StanleyLower TargetOverweight$360.00 ➝ $330.00
2/4/2022OppenheimerLower TargetOutperform$350.00 ➝ $285.00
2/4/2022BarclaysLower TargetEqual Weight$244.00 ➝ $235.00
2/4/2022Robert W. BairdLower TargetNeutral$258.00 ➝ $224.00
2/4/2022BMO Capital MarketsDowngradeOutperform ➝ Market Perform$260.00 ➝ $238.00
2/3/2022Stifel NicolausLower Target$344.00 ➝ $304.00
1/24/2022Leerink PartnersLower TargetOutperform$325.00 ➝ $300.00
1/20/2022BarclaysLower TargetEqual Weight$280.00 ➝ $244.00
1/18/2022Morgan StanleyLower TargetOverweight$363.00 ➝ $360.00
1/18/2022HC WainwrightLower TargetBuy$452.00 ➝ $270.00
1/14/2022Bank of AmericaLower TargetNeutral ➝ Neutral$275.00 ➝ $245.00
1/13/2022GuggenheimDowngradeBuy ➝ Neutral$290.00 ➝ $202.00
1/12/2022MizuhoLower TargetNeutral$270.00 ➝ $207.00
1/12/2022WedbushLower TargetNeutral$249.00 ➝ $195.00
1/12/2022Piper SandlerDowngradeOverweight ➝ Neutral$362.00 ➝ $216.00
1/11/2022Needham & Company LLCLower TargetBuy$386.00 ➝ $328.00
1/10/2022Truist FinancialLower TargetBuy ➝ Buy$502.00 ➝ $343.00
1/6/2022Morgan StanleyLower TargetOverweight$440.00 ➝ $363.00
1/3/2022Robert W. BairdReiterated RatingNeutral ➝ Neutral$258.00
1/3/2022UBS GroupLower Target$390.00 ➝ $335.00
12/30/2021Wells Fargo & CompanyBoost Target$250.00 ➝ $284.00
12/23/2021Bank of AmericaLower TargetNeutral$295.00 ➝ $275.00
12/22/2021Truist FinancialLower TargetReduce ➝ Buy$502.00
12/22/2021OppenheimerLower TargetOutperform$390.00 ➝ $350.00
12/21/2021JPMorgan Chase & Co.Lower TargetNeutral$324.00 ➝ $276.00
12/21/2021Robert W. BairdLower TargetNeutral$296.00 ➝ $258.00
12/20/2021Leerink PartnersLower TargetOutperform$450.00 ➝ $325.00
12/8/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$250.00
12/6/2021The Goldman Sachs GroupInitiated CoverageNeutral$271.00
11/19/2021Royal Bank of CanadaLower TargetSector Perform$295.00 ➝ $277.00
11/18/2021BMO Capital MarketsInitiated CoverageOutperform$315.00
10/28/2021Cantor FitzgeraldLower TargetNeutral$316.00 ➝ $259.00
10/26/2021MizuhoLower TargetNeutral$300.00 ➝ $270.00
10/21/2021HC WainwrightReiterated RatingBuy$453.00
10/21/2021Truist FinancialLower TargetBuy$647.00 ➝ $502.00
10/21/2021Morgan StanleyLower TargetOverweight$447.00 ➝ $440.00
10/21/2021CowenBoost TargetOutperform$375.00 ➝ $450.00
10/21/2021OppenheimerDowngradeOverweight$450.00 ➝ $390.00
10/21/2021Royal Bank of CanadaLower TargetSector Perform$325.00 ➝ $295.00
10/20/2021Piper SandlerLower TargetOverweight$460.00 ➝ $390.00
10/19/2021Needham & Company LLCInitiated CoverageBuy$400.00 ➝ $399.00
10/18/2021Jefferies Financial GroupReiterated RatingBuy
10/15/2021Stifel NicolausLower TargetBuy$430.00 ➝ $344.00
10/15/2021Cantor FitzgeraldLower TargetNeutral$427.00 ➝ $327.00
10/12/2021Morgan StanleyLower TargetOverweight$455.00 ➝ $447.00
10/8/2021Jefferies Financial GroupLower TargetBuy$500.00 ➝ $400.00
10/8/2021BarclaysLower TargetEqual Weight$395.00 ➝ $290.00
10/5/2021HC WainwrightReiterated RatingBuy$452.00
10/5/2021Leerink PartnersReiterated RatingBuy
9/29/2021Royal Bank of CanadaLower TargetSector Perform$341.00 ➝ $326.00
9/24/2021Robert W. BairdInitiated CoverageHold$296.00
9/23/2021MizuhoInitiated CoverageHold$300.00
9/23/2021HC WainwrightReiterated RatingBuy$452.00
9/22/2021Needham & Company LLCInitiated CoverageBuy$400.00
9/16/2021UBS GroupBoost TargetPositive ➝ Buy$442.00 ➝ $475.00
9/15/2021Bank of AmericaLower TargetNeutral$400.00 ➝ $360.00
8/2/2021MizuhoBoost TargetNeutral$244.00 ➝ $300.00
7/27/2021Cantor FitzgeraldReiterated RatingNeutral$435.00 ➝ $327.51
7/23/2021Morgan StanleyBoost TargetOverweight$453.00 ➝ $455.00
7/23/2021Royal Bank of CanadaLower TargetSector Perform$361.00 ➝ $341.00
7/22/2021Stifel NicolausLower TargetAverage ➝ Buy$443.00 ➝ $430.00
7/19/2021Evercore ISISet TargetBuy$324.62
7/16/2021Morgan StanleyLower TargetOverweight$455.00 ➝ $453.00
7/11/2021Robert W. BairdSet TargetHold$358.16
6/28/2021Royal Bank of CanadaLower TargetSector Perform$400.00 ➝ $354.00
6/18/2021Piper SandlerUpgradeNeutral ➝ Overweight$384.00 ➝ $450.00
6/15/2021Bank of AmericaReiterated RatingBuy$415.00
6/14/2021The Goldman Sachs GroupBoost TargetAverage ➝ Neutral$246.00 ➝ $436.00
6/11/2021Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$500.00
6/10/2021UBS GroupUpgradeNeutral ➝ Buy$463.00
6/10/2021Leerink PartnersBoost TargetOutperform$380.00 ➝ $475.00
6/8/2021William BlairUpgradeMarket Perform ➝ Outperform
6/8/2021Royal Bank of CanadaBoost TargetSector Perform$259.00 ➝ $400.00
6/8/2021Jefferies Financial GroupBoost TargetBuy$450.00 ➝ $500.00
6/8/2021Morgan StanleyBoost TargetOverweight$343.00 ➝ $455.00
6/8/2021BarclaysBoost TargetEqual Weight$265.00 ➝ $395.00
6/8/2021HC WainwrightBoost TargetBuy$305.00 ➝ $452.00
6/8/2021CitigroupUpgradeSell ➝ Neutral
6/8/2021Atlantic SecuritiesUpgradeUnderweight ➝ Neutral$415.00
6/7/2021Robert W. BairdUpgradeUnderperform ➝ Neutral$216.00 ➝ $382.00
6/7/2021Raymond JamesUpgradeUnderperform ➝ Market Perform
6/7/2021CowenUpgradeMarket Perform ➝ Outperform$225.00 ➝ $450.00
6/7/2021Bank of AmericaUpgradeUnderperform ➝ Neutral$235.00 ➝ $400.00
5/18/2021OppenheimerBoost TargetOutperform$300.00 ➝ $325.00
4/23/2021HC WainwrightReiterated RatingBuy
4/19/2021Morgan StanleyLower TargetOverweight$351.00 ➝ $343.00
4/12/2021WedbushBoost TargetNeutral$236.00 ➝ $245.00
2/17/2021Cantor FitzgeraldLower TargetNeutral$278.00 ➝ $268.00
2/5/2021DZ BankDowngradeBuy ➝ Hold$264.00
2/4/2021Credit Suisse GroupLower TargetOutperform$388.00 ➝ $350.00
2/4/2021Leerink PartnersLower TargetPositive ➝ Outperform$430.00 ➝ $380.00
2/4/2021Morgan StanleyLower TargetOverweight$352.00 ➝ $351.00
2/4/2021HC WainwrightBoost TargetBuy$289.00 ➝ $305.00
2/3/2021Piper SandlerLower TargetNeutral$265.00 ➝ $250.00
1/29/2021Stifel NicolausUpgradeHold ➝ Buy$258.00 ➝ $358.00
1/19/2021Morgan StanleyLower TargetOverweight$357.00 ➝ $352.00
12/1/2020William BlairReiterated RatingMarket Perform
12/1/2020Royal Bank of CanadaBoost TargetReduce ➝ Sector Perform$249.00 ➝ $256.00
11/19/2020Royal Bank of CanadaBoost TargetSector Perform$244.00 ➝ $249.00
11/10/2020Truist FinancialDowngradeBuy$310.00 ➝ $443.00
11/10/2020DZ BankUpgradeHold ➝ Buy$265.00
11/9/2020Royal Bank of CanadaLower TargetSector Perform$263.00 ➝ $244.00
11/9/2020OppenheimerLower TargetOutperform$370.00 ➝ $330.00
11/9/2020MizuhoLower TargetNeutral$282.00 ➝ $244.00
11/9/2020HC WainwrightLower TargetBuy$318.00 ➝ $289.00
11/9/2020CowenDowngradeOutperform ➝ Market Perform$275.00 ➝ $215.00
11/9/2020Bank of AmericaDowngradeNeutral ➝ Underperform$240.00
11/9/2020Atlantic SecuritiesDowngradeNeutral ➝ Underweight$175.00
11/5/2020Leerink PartnersBoost TargetPositive ➝ Outperform$342.00 ➝ $402.00
11/5/2020BMO Capital MarketsUpgradeMarket Perform$280.00 ➝ $343.00
11/4/2020Bank of AmericaUpgradeUnderperform ➝ Neutral$230.00 ➝ $360.00
11/4/2020Jefferies Financial GroupUpgradeHold ➝ Buy$450.00
11/4/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$437.00 ➝ $390.00
11/3/2020Cantor FitzgeraldLower Target$339.00 ➝ $278.00
10/28/2020UBS GroupInitiated CoverageNeutral$268.00
10/27/2020MizuhoLower TargetNeutral$316.00 ➝ $282.00
10/22/2020HC WainwrightReiterated RatingBuy
10/22/2020OppenheimerLower TargetOutperform$360.00 ➝ $340.00
10/22/2020BarclaysLower TargetEqual Weight$275.00 ➝ $265.00
10/22/2020WedbushLower TargetNeutral$281.00 ➝ $244.00
10/22/2020Credit Suisse GroupLower TargetOutperform$359.00 ➝ $350.00
10/22/2020Morgan StanleyBoost TargetOverweight$355.00 ➝ $357.00
10/20/2020Piper SandlerLower TargetNeutral$270.00 ➝ $265.00
10/19/2020Royal Bank of CanadaLower TargetSector Perform$281.00 ➝ $268.00
10/15/2020Bank of AmericaLower TargetUnderperform$255.00 ➝ $235.00
10/13/2020Morgan StanleyLower TargetOverweight$357.00 ➝ $355.00
9/18/2020Royal Bank of CanadaLower TargetSector Perform$284.00 ➝ $277.00
9/13/2020JPMorgan Chase & Co.Reiterated RatingHold
8/19/2020Leerink PartnersLower TargetOutperform$350.00 ➝ $342.00
8/7/2020Credit Suisse GroupUpgradeNeutral ➝ Outperform$270.00 ➝ $375.00
8/7/2020OppenheimerBoost TargetOutperform$325.00 ➝ $360.00
7/31/2020Raymond JamesReiterated RatingSell
7/29/2020JPMorgan Chase & Co.Reiterated RatingHold$279.00
7/27/2020Morgan StanleyUpgradeUnderweight ➝ Overweight$263.00 ➝ $357.00
7/23/2020BMO Capital MarketsLower TargetMarket Perform$317.00 ➝ $280.00
7/22/2020MizuhoReiterated RatingHold$316.00
7/22/2020Wells Fargo & CompanyBoost TargetEqual Weight$311.00 ➝ $324.00
7/22/2020Stifel NicolausLower TargetPositive ➝ Hold$294.00 ➝ $284.00
7/16/2020OppenheimerReiterated RatingBuy$325.00
7/15/2020Morgan StanleyLower TargetUnderweight$301.00 ➝ $263.00
7/13/2020The Goldman Sachs GroupLower TargetNeutral$300.00 ➝ $257.00
7/10/2020William BlairReiterated RatingHold
7/8/2020SunTrust BanksReiterated RatingBuy$330.00
7/8/2020GuggenheimReiterated RatingBuy$390.00
7/6/2020Royal Bank of CanadaReiterated RatingHold$276.00
6/25/2020Credit Suisse GroupReiterated RatingHold$270.00
6/22/2020Royal Bank of CanadaLower TargetSector Perform$303.00 ➝ $273.00
6/22/2020BarclaysDowngradeOverweight ➝ Equal Weight$370.00 ➝ $280.00
6/19/2020JPMorgan Chase & Co.Reiterated RatingHold
6/19/2020William BlairReiterated RatingHold
6/19/2020Robert W. BairdLower TargetUnderperform$290.00 ➝ $228.00
6/19/2020Credit Suisse GroupLower TargetNeutral$310.00 ➝ $270.00
6/19/2020Piper SandlerLower TargetNeutral$307.00 ➝ $260.00
6/18/2020MizuhoReiterated RatingHold$316.00
6/9/2020Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$360.00 ➝ $297.00
5/28/2020Morgan StanleyReiterated RatingSell$301.00
5/1/2020Cantor FitzgeraldReiterated RatingNeutral$361.00 ➝ $308.00
4/30/2020Royal Bank of CanadaReiterated RatingHold$310.00
4/24/2020William BlairReiterated RatingHold
4/23/2020Morgan StanleyLower TargetUnderweight$302.00 ➝ $301.00
4/23/2020SunTrust BanksLower TargetBuy$360.00 ➝ $330.00
4/23/2020OppenheimerLower TargetOutperform$390.00 ➝ $365.00
4/23/2020Credit Suisse GroupLower TargetNeutral$344.00 ➝ $310.00
4/23/2020BarclaysLower TargetOverweight$389.00 ➝ $370.00
4/23/2020Royal Bank of CanadaLower TargetSector Perform$325.00 ➝ $310.00
4/23/2020CitigroupDowngradeNeutral ➝ Sell$365.00 ➝ $240.00
4/22/2020Raymond JamesDowngradeMarket Perform ➝ Underperform
4/22/2020Stifel NicolausLower TargetHold$296.00 ➝ $294.00
4/22/2020WedbushLower TargetNeutral$306.00 ➝ $295.00
4/22/2020MizuhoReiterated RatingHold$316.00
4/8/2020Leerink PartnersReiterated RatingOutperform
3/31/2020Wolfe ResearchInitiated CoverageMarket Perform$331.00
3/18/2020Royal Bank of CanadaReiterated RatingHold$335.00
2/27/2020BarclaysInitiated CoverageOverweight$389.00
2/25/2020MizuhoBoost TargetNeutral$300.00 ➝ $316.00
2/11/2020William BlairReiterated RatingMarket Perform
2/7/2020OppenheimerBoost Target$338.00 ➝ $390.00
2/7/2020Nomura SecuritiesBoost TargetBuy$320.00 ➝ $392.00
2/6/2020BMO Capital MarketsReiterated RatingMarket Perform$317.00
2/6/2020Morgan StanleyBoost TargetUnderweight$261.00 ➝ $302.00
2/6/2020Leerink PartnersBoost TargetOutperform ➝ Positive$350.00 ➝ $410.00
2/6/2020Credit Suisse GroupBoost TargetNeutral$300.00 ➝ $330.00
2/6/2020Wells Fargo & CompanyBoost TargetEqual Weight$286.00 ➝ $311.00
2/6/2020JPMorgan Chase & Co.Reiterated RatingHold
2/6/2020HC WainwrightReiterated RatingBuy$335.00
2/6/2020Cantor FitzgeraldBoost TargetNeutral$315.00 ➝ $361.00
2/5/2020MizuhoReiterated RatingHold$300.00
2/5/2020Robert W. BairdBoost TargetUnderperform ➝ Underperform$250.00 ➝ $290.00
2/3/2020Leerink PartnersBoost TargetOutperform$350.00 ➝ $410.00
2/3/2020SunTrust BanksBoost TargetBuy$337.00 ➝ $360.00
2/2/2020Credit Suisse GroupReiterated RatingOverweight ➝ Hold$330.00 ➝ $300.00
1/31/2020Morgan StanleyLower TargetUnderweight$270.00 ➝ $261.00
1/31/2020Cantor FitzgeraldBoost TargetPositive ➝ Neutral$300.00 ➝ $315.00
1/30/2020WedbushReiterated RatingNeutral
1/30/2020JPMorgan Chase & Co.Reiterated RatingHold
1/27/2020Royal Bank of CanadaReiterated RatingHold$285.00
1/23/2020Credit Suisse GroupReiterated RatingHold$300.00
1/23/2020Robert W. BairdReiterated RatingSell$250.00
1/17/2020Morgan StanleyBoost TargetUnderweight$262.00 ➝ $270.00
1/2/2020CowenReiterated RatingBuy$325.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.87 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 41 very positive mentions
  • 53 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
5/25/2024
  • 31 very positive mentions
  • 69 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
6/24/2024
  • 29 very positive mentions
  • 77 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
7/24/2024
  • 40 very positive mentions
  • 45 positive mentions
  • 12 negative mentions
  • 2 very negative mentions
8/23/2024
  • 36 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/22/2024
  • 27 very positive mentions
  • 22 positive mentions
  • 3 negative mentions
  • 4 very negative mentions
10/22/2024
  • 51 very positive mentions
  • 61 positive mentions
  • 8 negative mentions
  • 5 very negative mentions
11/21/2024
  • 52 very positive mentions
  • 27 positive mentions
  • 10 negative mentions
  • 3 very negative mentions
12/21/2024

Current Sentiment

  • 52 very positive mentions
  • 27 positive mentions
  • 10 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Biogen logo
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $146.47
Low: $145.07
High: $147.85

50 Day Range

MA: $167.48
Low: $146.47
High: $191.56

52 Week Range

Now: $146.47
Low: $145.07
High: $268.30

Volume

5,775,622 shs

Average Volume

1,216,867 shs

Market Capitalization

$21.34 billion

P/E Ratio

13.23

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Biogen?

The following Wall Street analysts have issued reports on Biogen in the last twelve months: Bank Of America (Bofa), Bank of America Co., Barclays PLC, BMO Capital Markets, BTIG Research, Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., HC Wainwright, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, Scotiabank, Stifel Nicolaus, StockNews.com, TD Cowen, Truist Financial Co., UBS Group AG, Wedbush, Wells Fargo & Company, William Blair, and Wolfe Research.
View the latest analyst ratings for BIIB.

What is the current price target for Biogen?

0 Wall Street analysts have set twelve-month price targets for Biogen in the last year. Their average twelve-month price target is $242.68, suggesting a possible upside of 65.7%. HSBC Holdings plc has the highest price target set, predicting BIIB will reach $342.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $164.00 for Biogen in the next year.
View the latest price targets for BIIB.

What is the current consensus analyst rating for Biogen?

Biogen currently has 16 hold ratings and 13 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BIIB, but not buy more shares or sell existing shares.
View the latest ratings for BIIB.

What other companies compete with Biogen?

How do I contact Biogen's investor relations team?

Biogen's physical mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company's listed phone number is (617) 679-2000 and its investor relations email address is ir@biogen.com. The official website for Biogen is www.biogen.com. Learn More about contacing Biogen investor relations.





Receive Biogen News & Ratings Daily
Sign up to receive the latest news and ratings for Biogen and its competitors with PriceTargets.com’s free daily newsletter.